Blockade of central ghrelin receptor can treat NAFLD possibly via the hypothalamic PI3K/Akt/mTOR signaling pathway to improve insulin resistance. This evidence concerns the gene AKT1 and metabolic dysfunction-associated steatotic liver disease.